AlloVir, Inc. (ALVR)の価格はいくらですか

AlloVir, Inc. (ALVR)の価格は$9.81です

AlloVir, Inc. (ALVR)の時価総額は何ですか

AlloVir, Inc. (ALVR)の時価総額は$48.68Mです

AlloVir, Inc. (ALVR) の収益

AlloVir, Inc. is a biotechnology company in the clinical stage, dedicated to researching and developing allogeneic, "off-the-shelf" multi-virus specific T-cell (VST) therapies. Its primary goal is to prevent and treat severe diseases caused by viral infections. The company's lead product, posoleucel, is an allogeneic, ready-to-use VST therapy designed to combat several significant viruses, including BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Beyond this flagship candidate, AlloVir's pipeline features additional investigational treatments in various stages of development. These include ALVR106, which targets respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109, developed to address SARS-CoV-2 and COVID-19; ALVR107, for treating hepatitis B; and ALVR108. Established in 2013, the company was initially known as ViraCyte, Inc. before officially rebranding as AlloVir, Inc. in May 2019. Its headquarters are located in Waltham, Massachusetts.

年	収益	変化
2026 (TTM)	0.00	0.00%
2024	0.00	0.00%
2023	0.00	0.00%
2022	0.00	0.00%
2021	0.00	0.00%
2020	0.00	-100.00%
2019	$165.00K	-85.46%
2018	$1.14M	0.00%

年

収益

変化

2026 (TTM)

0.00

0.00%

2024

0.00

0.00%

2023

0.00

0.00%

2022

0.00

0.00%

2021

0.00

0.00%

2020

0.00

-100.00%

2019

$165.00K

-85.46%

2018

$1.14M

0.00%

企業	収益	収益の差	国
Vertex Pharmaceuticals Incorporated VRTX.US	$12.62B	-	US
Argenx SE ARGX.US	$6.02B	-	NL
CSL Limited CSL.AX	$15.70B	-	AU
Lonza Group AG LONN.SW	-	-	CH
Moderna, Inc. MRNA.US	$2.23B	-	US

企業

収益

収益の差

国